1
|
Ajamgard M, Sardroodi JJ, Ebrahimzadeh AR. A Molecular Dynamics Study of the Inhibition of Monomeric HIV‐1 Protease as An Alternative to Overcome Drug Resistance by RNA Aptamers as A Therapeutic Tool. ChemistrySelect 2020. [DOI: 10.1002/slct.202000990] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- Marzieh Ajamgard
- Department of ChemistryFaculty of Basic SciencesAzarbaijan Shahid Madani University Tabriz Iran
| | | | | |
Collapse
|
2
|
Marshall GR, Ballante F. Limiting Assumptions in the Design of Peptidomimetics. Drug Dev Res 2017; 78:245-267. [DOI: 10.1002/ddr.21406] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Garland R. Marshall
- Department of Biochemistry and Molecular Biophysics; Washington University School of Medicine; St. Louis Missouri 63110
| | - Flavio Ballante
- Department of Biochemistry and Molecular Biophysics; Washington University School of Medicine; St. Louis Missouri 63110
| |
Collapse
|
3
|
Veselovsky AV, Zharkova MS, Poroikov VV, Nicklaus MC. Computer-aided design and discovery of protein-protein interaction inhibitors as agents for anti-HIV therapy. SAR AND QSAR IN ENVIRONMENTAL RESEARCH 2014; 25:457-471. [PMID: 24716798 DOI: 10.1080/1062936x.2014.898689] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Protein-protein interactions (PPI) are involved in most of the essential processes that occur in organisms. In recent years, PPI have become the object of increasing attention in drug discovery, particularly for anti-HIV drugs. Although the use of combinations of existing drugs, termed highly active antiretroviral therapy (HAART), has revolutionized the treatment of HIV/AIDS, problems with these agents, such as the rapid emergence of drug-resistant HIV-1 mutants and serious adverse effects, have highlighted the need for further discovery of new drugs and new targets. Numerous investigations have shown that PPI play a key role in the virus's life cycle and that blocking or modulating them has a significant therapeutic potential. Here we summarize the recent progress in computer-aided design of PPI inhibitors, mainly focusing on the selection of the drug targets (HIV enzymes and virus entry machinery) and the utilization of peptides and small molecules to prevent a variety of protein-protein interactions (viral-viral or viral-host) that play a vital role in the progression of HIV infection.
Collapse
Affiliation(s)
- A V Veselovsky
- a Orekhovich Institute of Biomedical Chemistry of the Russian Academy of Medical Sciences , Moscow , Russia
| | | | | | | |
Collapse
|
4
|
Sayer JM, Aniana A, Louis JM. Mechanism of dissociative inhibition of HIV protease and its autoprocessing from a precursor. J Mol Biol 2012; 422:230-44. [PMID: 22659320 PMCID: PMC3418415 DOI: 10.1016/j.jmb.2012.05.024] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2012] [Revised: 05/15/2012] [Accepted: 05/15/2012] [Indexed: 11/17/2022]
Abstract
Dimerization is indispensible for release of the human immunodeficiency virus protease (PR) from its precursor (Gag-Pol) and ensuing mature-like catalytic activity that is crucial for virus maturation. We show that a single-chain Fv fragment (scFv) of a previously reported monoclonal antibody (mAb1696), which recognizes the N-terminus of PR, dissociates a dimeric mature D25N PR mutant with an enhanced dimer dissociation constant (K(d)) in the sub-micromolar range to form predominantly a monomer-scFv complex at a 1:1 ratio, along with small (5-10%) amounts of a dimer-scFv complex. Enzyme kinetics indicate a mixed mechanism of inhibition of the wild-type PR, which exhibits a K(d)<10nM, with effects both on K(m) and k(cat) at an scFv-to-PR ratio of 10:1. ScFv binds to the N-terminal peptide P(1)QITLW(6) of PR and to PR monomers with dissociation constants of ≤30 nM and ~100 nM, respectively. Consistent with an ~400-fold increase in the dissociation of the antibody (K(Ab)) on even addition of an acetyl group to P(1) of the peptide, the antibody fails to inhibit N-terminal autoprocessing of the PR from a model precursor (at ~5 μM). However, subsequent to this cleavage, it sequesters the PR, thus blocking autoprocessing at its C-terminus. A second monoclonal antibody [PRM1 (human monoclonal antibody to PR)], which recognizes part of the flap region (residues 41-47) of the mature PR and its precursor, does not inhibit autoprocessing and ensuing catalytic activity. However, its failure to recognize drug-resistant clinical mutants of PR may be beneficial to monitor the selection of mutations in this region under drug pressure.
Collapse
Affiliation(s)
| | | | - John M. Louis
- Corresponding author: John M. Louis, Building 5, Room B2-29, LCP, NIDDK, NIH, Bethesda, MD 20892-0520, Tel. 301 594-3122; Fax. 301 480-4001;
| |
Collapse
|
5
|
Yang H, Nkeze J, Zhao RY. Effects of HIV-1 protease on cellular functions and their potential applications in antiretroviral therapy. Cell Biosci 2012; 2:32. [PMID: 22971934 PMCID: PMC3490751 DOI: 10.1186/2045-3701-2-32] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2012] [Accepted: 08/31/2012] [Indexed: 11/10/2022] Open
Abstract
Human Immunodeficiency Virus Type 1 (HIV-1) protease inhibitors (PIs) are the most potent class of drugs in antiretroviral therapies. However, viral drug resistance to PIs could emerge rapidly thus reducing the effectiveness of those drugs. Of note, all current FDA-approved PIs are competitive inhibitors, i.e., inhibitors that compete with substrates for the active enzymatic site. This common inhibitory approach increases the likelihood of developing drug resistant HIV-1 strains that are resistant to many or all current PIs. Hence, new PIs that move away from the current target of the active enzymatic site are needed. Specifically, allosteric inhibitors, inhibitors that prohibit PR enzymatic activities through non-competitive binding to PR, should be sought. Another common feature of current PIs is they were all developed based on the structure-based design. Drugs derived from a structure-based strategy may generate target specific and potent inhibitors. However, this type of drug design can only target one site at a time and drugs discovered by this method are often associated with strong side effects such as cellular toxicity, limiting its number of target choices, efficacy, and applicability. In contrast, a cell-based system may provide a useful alternative strategy that can overcome many of the inherited shortcomings associated with structure-based drug designs. For example, allosteric PIs can be sought using a cell-based system without considering the site or mechanism of inhibition. In addition, a cell-based system can eliminate those PIs that have strong cytotoxic effect. Most importantly, a simple, economical, and easy-to-maintained eukaryotic cellular system such as yeast will allow us to search for potential PIs in a large-scaled high throughput screening (HTS) system, thus increasing the chances of success. Based on our many years of experience in using fission yeast as a model system to study HIV-1 Vpr, we propose the use of fission yeast as a possible surrogate system to study the effects of HIV-1 protease on cellular functions and to explore its utility as a HTS system to search for new PIs to battle HIV-1 resistant strains.
Collapse
Affiliation(s)
- Hailiu Yang
- Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA.
| | | | | |
Collapse
|
6
|
Bonomi M, Barducci A, Gervasio FL, Parrinello M. Multiple routes and milestones in the folding of HIV-1 protease monomer. PLoS One 2010; 5:e13208. [PMID: 20967249 PMCID: PMC2954147 DOI: 10.1371/journal.pone.0013208] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2010] [Accepted: 09/11/2010] [Indexed: 11/25/2022] Open
Abstract
Proteins fold on a time scale incompatible with a mechanism of random search in conformational space thus indicating that somehow they are guided to the native state through a funneled energetic landscape. At the same time the heterogeneous kinetics suggests the existence of several different folding routes. Here we propose a scenario for the folding mechanism of the monomer of HIV–1 protease in which multiple pathways and milestone events coexist. A variety of computational approaches supports this picture. These include very long all-atom molecular dynamics simulations in explicit solvent, an analysis of the network of clusters found in multiple high-temperature unfolding simulations and a complete characterization of free-energy surfaces carried out using a structure-based potential at atomistic resolution and a combination of metadynamics and parallel tempering. Our results confirm that the monomer in solution is stable toward unfolding and show that at least two unfolding pathways exist. In our scenario, the formation of a hydrophobic core is a milestone in the folding process which must occur along all the routes that lead this protein towards its native state. Furthermore, the ensemble of folding pathways proposed here substantiates a rational drug design strategy based on inhibiting the folding of HIV–1 protease.
Collapse
Affiliation(s)
- Massimiliano Bonomi
- Computational Science, Department of Chemistry and Applied Biosciences, ETH Zurich, Lugano, Switzerland.
| | | | | | | |
Collapse
|
7
|
Lee SG, Chmielewski J. Cross-linked peptoid-based dimerization inhibitors of HIV-1 protease. Chembiochem 2010; 11:1513-6. [PMID: 20575134 PMCID: PMC4441096 DOI: 10.1002/cbic.201000248] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2010] [Indexed: 11/07/2022]
Affiliation(s)
- Song-Gil Lee
- Department of Chemistry Purdue University 560 Oval Drive, West Lafayette, Indiana 47907 (USA)
| | - Jean Chmielewski
- Department of Chemistry Purdue University 560 Oval Drive, West Lafayette, Indiana 47907 (USA)
| |
Collapse
|
8
|
Analysis and characterization of dimerization inhibition of a multi-drug-resistant human immunodeficiency virus type 1 protease using a novel size-exclusion chromatographic approach. Biochem J 2009; 419:497-506. [PMID: 19149765 DOI: 10.1042/bj20082068] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Active-site inhibitors of HIV-1 PR (protease) block viral replication by preventing viral maturation. However, HIV-1 often develops resistance to active-site inhibitors through multiple mutations in PR and therefore recent efforts have focused on inhibiting PR dimerization as an alternative approach. Dimerization inhibitors have been identified using kinetic analysis, but additional characterization of the effect of these inhibitors on PR by physical methods has been difficult. In the present study, we identified a PR(MDR) (multi-drug-resistant HIV-1 PR) that was highly resistant to autoproteolysis. Using this PR and a novel size-exclusion chromatographic approach that incorporated fluorescence and MS detection, we were able to demonstrate inhibition of dimerization using P27 (peptide 27), a peptide dimerization inhibitor of PR previously identified on the basis of kinetic analysis. Incubation of PR(MDR) with P27, or other dimerization inhibitors, led to a dose- and time-dependent formation of PR monomers based on the change in elution time by size exclusion and its similar elution time to engineered forms of monomeric PR, namely PR(T26A) and glutathionylated PR. In contrast, incubation of PR(MDR) with a potent active-site inhibitor did not change the elution time for the PR(MDR) dimer. The monomeric PR induced by P27 had fluorescent characteristics which were consistent with unfolded PR. Structure-activity studies identified the active regions of P27 and experiments were performed to examine the effect of other dimerization inhibitors on PR. The present study is the first characterization of dimerization inhibition of PR(MDR), a prime target for these inhibitors, using a novel size-exclusion chromatographic approach.
Collapse
|
9
|
Verkhivker G. Computational proteomics analysis of binding mechanisms and molecular signatures of the HIV-1 protease drugs. Artif Intell Med 2009; 45:197-206. [DOI: 10.1016/j.artmed.2008.08.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2007] [Revised: 08/12/2008] [Accepted: 08/19/2008] [Indexed: 11/25/2022]
|
10
|
Abstract
During molecular recognition of proteins in biological systems, helices, reverse turns, and beta-sheets are dominant motifs. Often there are therapeutic reasons for blocking such recognition sites, and significant progress has been made by medicinal chemists in the design and synthesis of semirigid molecular scaffolds on which to display amino acid side chains. The basic premise is that preorganization of the competing ligand enhances the binding affinity and potential selectivity of the inhibitor. In this chapter, current progress in these efforts is reviewed.
Collapse
|
11
|
Bannwarth L, Rose T, Dufau L, Vanderesse R, Dumond J, Jamart-Grégoire B, Pannecouque C, De Clercq E, Reboud-Ravaux M. Dimer Disruption and Monomer Sequestration by Alkyl Tripeptides Are Successful Strategies for Inhibiting Wild-Type and Multidrug-Resistant Mutated HIV-1 Proteases. Biochemistry 2008; 48:379-87. [DOI: 10.1021/bi801422u] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Ludovic Bannwarth
- Enzymologie Moléculaire et Fonctionnelle, FRE 2852, CNRS, Université Paris 6 UPMC, Institut Jacques Monod, 2 place Jussieu, 75251 Paris Cedex 5, France, Institut Pasteur, PFBMI, Département de Biologie Structurale, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France, Laboratoire de Chimie Physique Macromoléculaire, UMR 7568 CNRS-INPL, ENSIC 1, rue Grandville, 54001 Nancy, France, and Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium
| | - Thierry Rose
- Enzymologie Moléculaire et Fonctionnelle, FRE 2852, CNRS, Université Paris 6 UPMC, Institut Jacques Monod, 2 place Jussieu, 75251 Paris Cedex 5, France, Institut Pasteur, PFBMI, Département de Biologie Structurale, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France, Laboratoire de Chimie Physique Macromoléculaire, UMR 7568 CNRS-INPL, ENSIC 1, rue Grandville, 54001 Nancy, France, and Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium
| | - Laure Dufau
- Enzymologie Moléculaire et Fonctionnelle, FRE 2852, CNRS, Université Paris 6 UPMC, Institut Jacques Monod, 2 place Jussieu, 75251 Paris Cedex 5, France, Institut Pasteur, PFBMI, Département de Biologie Structurale, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France, Laboratoire de Chimie Physique Macromoléculaire, UMR 7568 CNRS-INPL, ENSIC 1, rue Grandville, 54001 Nancy, France, and Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium
| | - Régis Vanderesse
- Enzymologie Moléculaire et Fonctionnelle, FRE 2852, CNRS, Université Paris 6 UPMC, Institut Jacques Monod, 2 place Jussieu, 75251 Paris Cedex 5, France, Institut Pasteur, PFBMI, Département de Biologie Structurale, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France, Laboratoire de Chimie Physique Macromoléculaire, UMR 7568 CNRS-INPL, ENSIC 1, rue Grandville, 54001 Nancy, France, and Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium
| | - Julien Dumond
- Enzymologie Moléculaire et Fonctionnelle, FRE 2852, CNRS, Université Paris 6 UPMC, Institut Jacques Monod, 2 place Jussieu, 75251 Paris Cedex 5, France, Institut Pasteur, PFBMI, Département de Biologie Structurale, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France, Laboratoire de Chimie Physique Macromoléculaire, UMR 7568 CNRS-INPL, ENSIC 1, rue Grandville, 54001 Nancy, France, and Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium
| | - Brigitte Jamart-Grégoire
- Enzymologie Moléculaire et Fonctionnelle, FRE 2852, CNRS, Université Paris 6 UPMC, Institut Jacques Monod, 2 place Jussieu, 75251 Paris Cedex 5, France, Institut Pasteur, PFBMI, Département de Biologie Structurale, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France, Laboratoire de Chimie Physique Macromoléculaire, UMR 7568 CNRS-INPL, ENSIC 1, rue Grandville, 54001 Nancy, France, and Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium
| | - Christophe Pannecouque
- Enzymologie Moléculaire et Fonctionnelle, FRE 2852, CNRS, Université Paris 6 UPMC, Institut Jacques Monod, 2 place Jussieu, 75251 Paris Cedex 5, France, Institut Pasteur, PFBMI, Département de Biologie Structurale, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France, Laboratoire de Chimie Physique Macromoléculaire, UMR 7568 CNRS-INPL, ENSIC 1, rue Grandville, 54001 Nancy, France, and Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium
| | - Erik De Clercq
- Enzymologie Moléculaire et Fonctionnelle, FRE 2852, CNRS, Université Paris 6 UPMC, Institut Jacques Monod, 2 place Jussieu, 75251 Paris Cedex 5, France, Institut Pasteur, PFBMI, Département de Biologie Structurale, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France, Laboratoire de Chimie Physique Macromoléculaire, UMR 7568 CNRS-INPL, ENSIC 1, rue Grandville, 54001 Nancy, France, and Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium
| | - Michèle Reboud-Ravaux
- Enzymologie Moléculaire et Fonctionnelle, FRE 2852, CNRS, Université Paris 6 UPMC, Institut Jacques Monod, 2 place Jussieu, 75251 Paris Cedex 5, France, Institut Pasteur, PFBMI, Département de Biologie Structurale, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France, Laboratoire de Chimie Physique Macromoléculaire, UMR 7568 CNRS-INPL, ENSIC 1, rue Grandville, 54001 Nancy, France, and Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium
| |
Collapse
|
12
|
Sidechain-linked inhibitors of HIV-1 protease dimerization. Bioorg Med Chem 2008; 17:967-76. [PMID: 18337105 DOI: 10.1016/j.bmc.2008.02.060] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2007] [Revised: 02/15/2008] [Accepted: 02/16/2008] [Indexed: 11/20/2022]
Abstract
There is a great need for alternative modes of inhibition for the design of anti-HIV therapies, due to the increased resistance of HIV to currently approved drugs. A novel strategy for generating potent dimerization inhibitors of HIV-1 protease is described based on sidechain-linked interfacial peptides. In a number of cases the activity of these agents against HIV-1 protease was found to be among the most potent reported, with inhibitory constants in the low nM range.
Collapse
|
13
|
Broglia RA, Levy Y, Tiana G. HIV-1 protease folding and the design of drugs which do not create resistance. Curr Opin Struct Biol 2008; 18:60-6. [DOI: 10.1016/j.sbi.2007.10.004] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2007] [Accepted: 10/29/2007] [Indexed: 10/22/2022]
|
14
|
Yan MC, Sha Y, Wang J, Xiong XQ, Ren JH, Cheng MS. Molecular dynamics simulations of HIV‐1 protease monomer: Assembly of N‐terminus and C‐terminus into β‐sheet in water solution. Proteins 2008; 70:731-8. [PMID: 17729281 DOI: 10.1002/prot.21539] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
HIV-1 protease (HIV-PR) consists of two identical subunits that are united together through a four-stranded antiparallel beta-sheet formed of the peptide termini of each monomer. Since the active site exists only in the dimer, a strategy that is attracting more and more attention in inhibitor design and which may overcome the serious drug resistance caused by competitive inhibitors is to block the peptide termini of the monomer, thereby interfering with formation of the active dimer. In the present work, we performed several extensive molecular dynamics (MD) simulations of the HIV-PR monomer in water to illustrate its solvated conformation and dynamics behavior. We found that the peptide termini usually assembled into beta-sheet after several nanoseconds' simulation, and became much less flexible. This beta-sheet is stabilized by intramolecular interactions and is not easily disaggregated under the present MD simulation conditions. This transformation may be an important transition during the relaxing and equilibrating of the HIV-PR monomer in aqueous solution, and the terminal beta-sheet may be one of the major conformations of the solvated HIV-PR monomer termini in water. This work may provide new insights into the dynamics behavior and dimerization mechanism of HIV-PR, and more significantly, offer a more rational receptor model for the design and discovery of novel dimerization inhibitors than crystalline structures.
Collapse
Affiliation(s)
- Mao-Cai Yan
- Key Laboratory of New Drugs Design and Discovery of Liaoning Province, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China
| | | | | | | | | | | |
Collapse
|
15
|
Ishima R, Torchia DA, Louis JM. Mutational and Structural Studies Aimed at Characterizing the Monomer of HIV-1 Protease and Its Precursor. J Biol Chem 2007; 282:17190-9. [PMID: 17412697 DOI: 10.1074/jbc.m701304200] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
An experimental protocol for folding the mature human immunodeficiency virus-1 (HIV-1) protease is presented that facilitates NMR studies at a low protein concentration of approximately 20 micoM. Under these conditions, NMR spectra show that the mature protease lacking its terminal beta-sheet residues 1-4 and 96-99 (PR(5-95)) exhibits a stable monomer fold spanning the region 10-90 that is similar to that of the single subunit of the wild-type dimer and the dimer bearing a D25N mutation (PR(D25N)). Urea-induced unfolding monitored both by changes in (1)H-(15)N heteronuclear single quantum correlation spectra and by protein fluorescence indicates that although PR(5-95) monomer displays a transition profile similar to that of the PR(D25N) dimer (50% unfolded (U(50)) = approximately 1.9 M), extending the protease with 4 residues (SFNF) of its N-terminally flanking sequence in the Gag-Pol precursor ((SFNF)PR(D25N)) decreases the stability of the fold (U(50) = approximately 1.5 M). Assigned backbone chemical shifts were used to elucidate differences in the stability of the PR(T26A) (U(50) = 2.5 M) and (SFNF)PR(D25N) monomers and compared with PR(D25N/T26A) monomer. Discernible differences in the backbone chemical shifts were observed for N-terminal protease residues 3-6 of (SFNF)PR(D25N) that may relate to the increase in the equilibrium dissociation constant (K(d)) and the very low catalytic activity of the protease prior to its autoprocessing at its N terminus from the Gag-Pol precursor.
Collapse
Affiliation(s)
- Rieko Ishima
- Department of Structural Biology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, USA
| | | | | |
Collapse
|
16
|
Pal-Bhowmick I, Krishnan S, Jarori GK. Differential susceptibility of Plasmodium falciparum versus yeast and mammalian enolases to dissociation into active monomers. FEBS J 2007; 274:1932-45. [PMID: 17371507 DOI: 10.1111/j.1742-4658.2007.05738.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
In the past, several unsuccessful attempts have been made to dissociate homodimeric enolases into their active monomeric forms. The main objective of these studies had been to understand whether intersubunit interactions are essential for the catalytic and structural stability of enolases. Further motivation to investigate the properties of monomeric enolase has arisen from several recent reports on the involvement of enolase in diverse nonglycolytic (moonlighting) functions, where it may occur in monomeric form. Here, we report successful dissociation of dimeric enolases from Plasmodium falciparum, yeast and rabbit muscle into active and isolatable monomers. Dimeric enolases could be dissociated into monomers by high concentrations ( approximately 250 mm) of imidazole and/or hydrogen ions. Two forms were separated using Superdex-75 gel filtration chromatography. A detailed comparison of the kinetic and structural properties of monomeric and dimeric forms of recombinant P. falciparum enolase showed differences in specific activity, salt-induced inhibition and inactivation, thermal stability, etc. Furthermore, we found that enolases from the three species differ in their dimer dissociation profiles. Specifically, on challenge with imidazole, Mg(II) protected the enolases of yeast and rabbit muscle but not of P. falciparum from dissociation. The observed differential stability of the P. falciparum enolase dimer interface with respect to mammalian enolases could be exploited to selectively dissociate the dimeric parasite enzyme into its catalytically inefficient, thermally unstable monomeric form. Thus enolase could be a novel therapeutic target for malaria.
Collapse
Affiliation(s)
- Ipsita Pal-Bhowmick
- Department of Biological Sciences, Tata Institute of Fundamental Research, Colaba, Mumbai, India
| | | | | |
Collapse
|
17
|
Louis JM, Ishima R, Torchia DA, Weber IT. HIV-1 protease: structure, dynamics, and inhibition. ADVANCES IN PHARMACOLOGY (SAN DIEGO, CALIF.) 2007; 55:261-98. [PMID: 17586318 DOI: 10.1016/s1054-3589(07)55008-8] [Citation(s) in RCA: 84] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- John M Louis
- Laboratory of Chemical Physics, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
| | | | | | | |
Collapse
|
18
|
Sirkis R, Gerst JE, Fass D. Ddi1, a eukaryotic protein with the retroviral protease fold. J Mol Biol 2006; 364:376-87. [PMID: 17010377 DOI: 10.1016/j.jmb.2006.08.086] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2006] [Revised: 08/25/2006] [Accepted: 08/29/2006] [Indexed: 10/24/2022]
Abstract
Retroviral aspartyl proteases are homodimeric, whereas eukaryotic aspartyl proteases tend to be large, monomeric enzymes with 2-fold internal symmetry. It has been proposed that contemporary monomeric aspartyl proteases evolved by gene duplication and fusion from a primordial homodimeric enzyme. Recent sequence analyses have suggested that such "fossil" dimeric aspartyl proteases are still encoded in the eukaryotic genome. We present evidence for retention of a dimeric aspartyl protease in eukaryotes. The X-ray crystal structure of a domain of the Saccharomyces cerevisiae protein Ddi1 shows that it is a dimer with a fold similar to that of the retroviral proteases. Furthermore, the double Asp-Thr-Gly-Ala amino acid sequence motif at the active site of HIV protease is found with identical geometry in the Ddi1 structure. However, the putative substrate binding groove is wider in Ddi1 than in the retroviral proteases, suggesting that Ddi1 accommodates bulkier substrates. Ddi1 belongs to a family of proteins known as the ubiquitin receptors, which have in common the ability to bind ubiquitinated substrates and the proteasome. Ubiquitin receptors contain an amino-terminal ubiquitin-like (UBL) domain and a carboxy-terminal ubiquitin-associated (UBA) domain, but Ddi1 is the only representative in which the UBL and UBA domains flank an aspartyl protease-like domain. The remarkable structural similarity between the central domain of Ddi1 and the retroviral proteases, in the global fold and in active-site detail, suggests that Ddi1 functions proteolytically during regulated protein turnover in the cell.
Collapse
Affiliation(s)
- Roy Sirkis
- Department of Structural Biology, Weizmann Institute of Science, Rehovot 76100, Israel
| | | | | |
Collapse
|
19
|
Masso M, Lu Z, Vaisman II. Computational mutagenesis studies of protein structure‐function correlations. Proteins 2006; 64:234-45. [PMID: 16617425 DOI: 10.1002/prot.20968] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Topological scores, measures of sequence-structure compatibility, are calculated for all 1,881 single point mutants of the human immunodeficiency virus (HIV)-1 protease using a four-body statistical potential function based on Delaunay tessellation of protein structure. Comparison of the mutant topological score data with experimental data from alanine scan studies specifically on the dimer interface residues supports previous findings that 1) L97 and F99 contribute greatly to the Gibbs energy of HIV-1 protease dimerization, 2) Q2 and T4 contribute the least toward the Gibbs energy, and 3) C-terminal residues are more sensitive to mutations than those at the N-terminus. For a more comprehensive treatment of the relationship between protease structure and function, mutant topological scores are compared with the activity levels for a set of 536 experimentally synthesized protease mutants, and a significant correlation is observed. Finally, this structure-function correlation is similarly identified by examining model systems consisting of 2,015 single point mutants of bacteriophage T4 lysozyme as well as 366 single point mutants of HIV-1 reverse transcriptase and is hypothesized to be a property generally applicable to all proteins.
Collapse
Affiliation(s)
- Majid Masso
- Laboratory for Structural Bioinformatics, School of Computational Sciences, George Mason University, Manassas, Virginia 20110, USA
| | | | | |
Collapse
|
20
|
Lee SG, Chmielewski J. Rapid Synthesis and In Situ Screening of Potent HIV-1 Protease Dimerization Inhibitors. ACTA ACUST UNITED AC 2006; 13:421-6. [PMID: 16632254 DOI: 10.1016/j.chembiol.2006.02.012] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2005] [Revised: 01/19/2006] [Accepted: 02/06/2006] [Indexed: 11/21/2022]
Abstract
A library of dimerization inhibitors of HIV-1 protease is described based on crosslinked interfacial peptides. The 54 component library was designed to contain two modifications to the starting structure, one each in the Northern and Southern fragments. A rapid synthesis and in situ screening method in microtiter plates was developed to facilitate the generation and evaluation of the library members. More than 90% of the doubly modified agents were more potent than their respective singly mutated parent compounds, and five of the most potent dimerization inhibitors of HIV-1 protease described to date were identified. The free energy of binding for the combined two modifications was generally found to be additive, demonstrating the predictive value of earlier libraries.
Collapse
Affiliation(s)
- Song-Gil Lee
- Department of Chemistry, Purdue University, West Lafayette, Indiana 47907, USA
| | | |
Collapse
|
21
|
Licini G, Prins LJ, Scrimin P. Oligopeptide Foldamers: From Structure to Function. European J Org Chem 2005. [DOI: 10.1002/ejoc.200400521] [Citation(s) in RCA: 83] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Giulia Licini
- University of Padova, Department of Chemical Sciences, and ITM‐CNR, Padova Section, Via Marzolo, 1, 35131 Padova, Italy
| | - Leonard J. Prins
- University of Padova, Department of Chemical Sciences, and ITM‐CNR, Padova Section, Via Marzolo, 1, 35131 Padova, Italy
| | - Paolo Scrimin
- University of Padova, Department of Chemical Sciences, and ITM‐CNR, Padova Section, Via Marzolo, 1, 35131 Padova, Italy
| |
Collapse
|
22
|
Westmeyer GG, Willem M, Lichtenthaler SF, Lurman G, Multhaup G, Assfalg-Machleidt I, Reiss K, Saftig P, Haass C. Dimerization of beta-site beta-amyloid precursor protein-cleaving enzyme. J Biol Chem 2004; 279:53205-12. [PMID: 15485862 DOI: 10.1074/jbc.m410378200] [Citation(s) in RCA: 91] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Cleavage of the beta-amyloid precursor protein (APP) by the aspartyl protease beta-site APP-cleaving enzyme (BACE) is the first step in the generation of the amyloid beta-peptide, which is deposited in the brain of Alzheimer's disease patients. Whereas the subsequent cleavage by gamma-secretase was shown to originate from the cooperation of a multicomponent complex, it is currently unknown whether in a cellular environment BACE is enzymatically active as a monomer or in concert with other proteins. Using blue native gel electrophoresis we found that endogenous and overexpressed BACE has a molecular mass of 140 kDa instead of the expected mass of 70 kDa under denaturing conditions. This suggests that under native conditions BACE exists as a homodimer. Homodimerization was confirmed by co-immunoprecipitation of full-length BACE carrying different epitope tags. In contrast, the soluble active BACE ectodomain was exclusively present as a monomer both under native and denaturing conditions. A domain analysis revealed that the BACE ectodomain dimerized as long as it was attached to the membrane, whereas the cytoplasmic domain and the transmembrane domain were dispensable for dimerization. By adding a KKXX-endoplasmic reticulum retention signal to BACE, we demonstrate that dimerization of BACE occurs already before full maturation and pro-peptide cleavage. Furthermore, kinetic analysis of the purified native BACE dimer revealed a higher affinity and turnover rate in comparison to the monomeric soluble BACE. Dimerization of BACE might, thus, facilitate binding and cleavage of physiological substrates.
Collapse
Affiliation(s)
- Gil G Westmeyer
- Adolf Butenandt Institute, Department of Biochemistry, Laboratory for Alzheimer's and Parkinson's Disease Research, Schillerstrasse 44, Ludwig Maximilians University, 80336 Munich, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Hwang YS, Chmielewski J. A unidirectional crosslinking strategy for HIV-1 protease dimerization inhibitors. Bioorg Med Chem Lett 2004; 14:4297-300. [PMID: 15261290 DOI: 10.1016/j.bmcl.2004.05.081] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2004] [Revised: 05/28/2004] [Accepted: 05/28/2004] [Indexed: 11/19/2022]
Abstract
A novel strategy to identify potent HIV-1 protease dimerization inhibitors was developed using 12-aminododecanoic acid as a tether to crosslink interfacial peptides. The directionality of the southern peptide was changed from N-->C to C-->N as compared to previously reported inhibitors. The terminal amine of the southern peptide and side chains were further diversified to find essential functional groups for dimerization inhibition of HIV-1 protease.
Collapse
Affiliation(s)
- You Seok Hwang
- Department of Chemistry, Purdue University, West Lafayette, IN 47906, USA
| | | |
Collapse
|
24
|
Shultz MD, Ham YW, Lee SG, Davis DA, Brown C, Chmielewski J. Small-Molecule Dimerization Inhibitors of Wild-Type and Mutant HIV Protease: A Focused Library Approach. J Am Chem Soc 2004; 126:9886-7. [PMID: 15303839 DOI: 10.1021/ja048139n] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
We demonstrate that a focused library based on truncated, cross-linked interfacial peptides of HIV-1 protease produces effective dimerization inhibitors of the enzyme. By combining individual changes of the library into a single compound, we obtained a significantly more potent agent and found that an additive increase in inhibitor efficacy was obtained. The good activity of library members against an active-site drug-resistant protease mutant bodes well for dimerization inhibition as a complementary method to targeting the active site.
Collapse
Affiliation(s)
- Michael D Shultz
- Department of Chemistry, Purdue University, West Lafayette, Indiana 47907, USA
| | | | | | | | | | | |
Collapse
|
25
|
Levy Y, Caflisch A, Onuchic JN, Wolynes PG. The folding and dimerization of HIV-1 protease: evidence for a stable monomer from simulations. J Mol Biol 2004; 340:67-79. [PMID: 15184023 DOI: 10.1016/j.jmb.2004.04.028] [Citation(s) in RCA: 83] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2003] [Revised: 03/27/2004] [Accepted: 04/03/2004] [Indexed: 11/18/2022]
Abstract
HIV-1 protease (PR) is a major drug target in combating AIDS, as it plays a key role in maturation and replication of the virus. Six FDA-approved drugs are currently in clinical use, all designed to inhibit enzyme activity by blocking the active site, which exists only in the dimer. An alternative inhibition mode would be required to overcome the emergence of drug-resistance through the accumulation of mutations. This might involve inhibiting the formation of the dimer itself. Here, the folding of HIV-1 PR dimer is studied with several simulation models appropriate for folding mechanism studies. Simulations with an off-lattice Gō-model, which corresponds to a perfectly funneled energy landscape, indicate that the enzyme is formed by association of structured monomers. All-atom molecular dynamics simulations strongly support the stability of an isolated monomer. The conjunction of results from a model that focuses on the protein topology and a detailed all-atom force-field model suggests, in contradiction to some reported equilibrium denaturation experiments, that monomer folding and dimerization are decoupled. The simulation result is, however, in agreement with the recent NMR detection of folded monomers of HIV-1 PR mutants with a destabilized interface. Accordingly, the design of dimerization inhibitors should not focus only on the flexible N and C termini that constitute most of the dimer interface, but also on other structured regions of the monomer. In particular, the relatively high phi values for residues 23-35 and 79-87 in both the folding and binding transition states, together with their proximity to the interface, highlight them as good targets for inhibitor design.
Collapse
Affiliation(s)
- Yaakov Levy
- Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland.
| | | | | | | |
Collapse
|
26
|
Zhao L, O'Reilly MK, Shultz MD, Chmielewski J. Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization. Bioorg Med Chem Lett 2003; 13:1175-7. [PMID: 12643937 DOI: 10.1016/s0960-894x(03)00040-4] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Peptides derived from the interfacial region of dimeric HIV-1 integrase were evaluated as inhibitors of integrase's 3'-endonuclease activity. Three peptides were found to be moderately potent inhibitors with IC(50) values in the low micromolar range. The mode of inhibition was probed through protein crosslinking experiments. Active interfacial peptides were found to inhibit crosslinking of the dimeric form of integrase. Interfacial peptides that were poor inhibitors had no effect on integrase crosslinking.
Collapse
Affiliation(s)
- Lei Zhao
- Department of Chemistry, Purdue University, West Lafayette, IN 47907, USA
| | | | | | | |
Collapse
|